· PDUFA target date set for December 19 by the FDA · Runway significantly extended Lund, Sweden, 23 April 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report January-March 2026. Read more…
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1.3 patency‑related reintervention rate per patient year) and a 3% clinically relevant access related infection rate CE mark approval enables Xeltis to […]
CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess™ reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN, The Netherlands – 21 April, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tumor immune response to benefit cancer patients in need Lund, Sweden, 17 April 2026 – Asgard Therapeutics, a privately held biotech company pioneering […]
Report outlines 17 targeted actions to address structural barriers hindering leadership progression Copenhagen / Oslo / Stockholm, April 17, 2026 — The Nordic life science sector is losing highly qualified female talent in top leadership positions, according to a new white paper published by Women in Life Science Denmark (WiLD), WiLD Norway, and VILDA Sweden. […]
